At 10.7x trailing earnings and just 7.6x forward earnings with a PEG of 0.7, the stock is priced as if growth is either low quality or at risk of deterioration. The market cap of $829M against a Price/Sales of 0.5 and Price/Book of 1.2 signals clear deep value territory, yet the Altman Z-Score of 2.3 keeps it out of the financial safety zone and implies moderate balance sheet stress risk. With ROE at only 3.30% and ROIC at 4.70%, capital efficiency is weak, suggesting the low multiple is at least partially justified. This is not a pristine compounder; it is a statistically cheap cyclical with middling returns that the market is discounting for structural risk rather than ignoring outright.
⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.